Cas9-Tmc1-mut3 RNP genome editing agent shows promise in model of autosomal dominant hearing loss Jan. 9, 2018
Frequency Therapeutics completes first-in-human study of drug candidate for hearing loss Dec. 22, 2017
NXT-596 demonstrates gamma-secretase inhibition as a therapeutic strategy against hearing loss Nov. 20, 2017
Ebselen proves to be safe and effective in preventing noise-induced hearing loss in phase II study Aug. 16, 2017
Auris Medical completes acquisition of intranasal betahistine assets from Otifex Therapeutics July 21, 2017
RSS